Over-the-counter triptans for migraine : what are the implications?

Area of Science:

• Neurology
• Pharmacology
• Public Health

Background:

• Sumatriptan and naratriptan became available as over-the-counter (OTC) medications in the UK and Germany in 2006.
• These triptans have established safety profiles from extensive patient use.
• Migraine imposes a significant economic burden, primarily due to lost productivity.

Purpose of the Study:

• To evaluate the implications of OTC triptan availability for clinical practice and patient management.
• To highlight the potential benefits of early migraine self-treatment with triptans.
• To address the risks of medication overuse and the need for patient and pharmacist education.

Main Methods:

• Review of the clinical use and safety data of OTC triptans.
• Analysis of the economic impact of migraine and potential cost savings.
• Discussion of clinical practice adjustments and educational requirements for pharmacists.

Main Results:

• OTC triptans facilitate earlier patient self-medication, potentially improving outcomes.
• Increased access may lead to better migraine management and reduced disability.
• A significant economic opportunity exists in reducing migraine-related productivity losses.

Conclusions:

• OTC availability of triptans represents a logical advancement in managing migraine.
• Crucial need for patient counseling on medication overuse (limit use to <10 days/month).
• Essential to train pharmacists on migraine diagnosis and triptan contraindications for safe dispensing.